AMGN
Price
$293.85
Change
+$1.45 (+0.50%)
Updated
Oct 14 closing price
Capitalization
158.2B
20 days until earnings call
Intraday Buy/Sell Signals
BIIB
Price
$145.31
Change
+$0.62 (+0.43%)
Updated
Oct 14 closing price
Capitalization
21.3B
15 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

AMGN vs BIIB

Header iconAMGN vs BIIB Comparison
Open Charts AMGN vs BIIBBanner chart's image
Amgen
Price$293.85
Change+$1.45 (+0.50%)
Volume$1.98M
Capitalization158.2B
Biogen
Price$145.31
Change+$0.62 (+0.43%)
Volume$1.28M
Capitalization21.3B
AMGN vs BIIB Comparison Chart in %
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. BIIB commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BIIB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (AMGN: $293.85 vs. BIIB: $145.31)
Brand notoriety: AMGN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 87% vs. BIIB: 78%
Market capitalization -- AMGN: $158.2B vs. BIIB: $21.3B
AMGN [@Pharmaceuticals: Major] is valued at $158.2B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $21.3B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $728.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $96.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 2 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • AMGN’s FA Score: 2 green, 3 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, AMGN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 6 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 4 bearish.
  • BIIB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -0.57% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -4.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.70%. For the same industry, the average monthly price growth was +0.81%, and the average quarterly price growth was +19.36%.

Reported Earning Dates

AMGN is expected to report earnings on Nov 04, 2025.

BIIB is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.70% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($158B) has a higher market cap than BIIB($21.3B). AMGN has higher P/E ratio than BIIB: AMGN (24.03) vs BIIB (13.91). AMGN YTD gains are higher at: 15.587 vs. BIIB (-4.976). AMGN has higher annual earnings (EBITDA): 15.9B vs. BIIB (2.79B). AMGN has more cash in the bank: 8.03B vs. BIIB (2.76B). BIIB has less debt than AMGN: BIIB (6.6B) vs AMGN (56.2B). AMGN has higher revenues than BIIB: AMGN (34.9B) vs BIIB (10B).
AMGNBIIBAMGN / BIIB
Capitalization158B21.3B742%
EBITDA15.9B2.79B569%
Gain YTD15.587-4.976-313%
P/E Ratio24.0313.91173%
Revenue34.9B10B349%
Total Cash8.03B2.76B291%
Total Debt56.2B6.6B852%
FUNDAMENTALS RATINGS
AMGN vs BIIB: Fundamental Ratings
AMGN
BIIB
OUTLOOK RATING
1..100
179
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
91
Overvalued
PROFIT vs RISK RATING
1..100
39100
SMR RATING
1..100
1474
PRICE GROWTH RATING
1..100
5447
P/E GROWTH RATING
1..100
9759
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (15) in the Biotechnology industry is significantly better than the same rating for BIIB (91). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

AMGN's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for BIIB (100). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.

AMGN's SMR Rating (14) in the Biotechnology industry is somewhat better than the same rating for BIIB (74). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's Price Growth Rating (47) in the Biotechnology industry is in the same range as AMGN (54). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.

BIIB's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for AMGN (97). This means that BIIB’s stock grew somewhat faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNBIIB
RSI
ODDS (%)
N/A
Bearish Trend 8 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
52%
Bearish Trend 8 days ago
63%
Momentum
ODDS (%)
Bullish Trend 8 days ago
59%
Bullish Trend 8 days ago
57%
MACD
ODDS (%)
Bullish Trend 8 days ago
61%
Bullish Trend 8 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 8 days ago
55%
Bearish Trend 8 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
55%
Bullish Trend 8 days ago
58%
Advances
ODDS (%)
Bullish Trend 15 days ago
56%
Bullish Trend 13 days ago
56%
Declines
ODDS (%)
Bearish Trend 21 days ago
52%
Bearish Trend 8 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
60%
Bearish Trend 8 days ago
78%
Aroon
ODDS (%)
Bearish Trend 8 days ago
49%
Bullish Trend 8 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BDSX7.790.39
+5.27%
Biodesix Inc
EXPI10.980.47
+4.47%
eXp World Holdings
WTFC131.703.27
+2.55%
Wintrust Financial Corp
WHLRP4.09-0.03
-0.73%
Wheeler Real Estate Investment Trust
CGEM7.74-0.09
-1.15%
Cullinan Therapeutics

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with ABBV. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then ABBV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.49%
ABBV - AMGN
57%
Loosely correlated
-0.51%
NVS - AMGN
54%
Loosely correlated
+0.88%
BIIB - AMGN
53%
Loosely correlated
+0.43%
PFE - AMGN
53%
Loosely correlated
-0.85%
MRK - AMGN
51%
Loosely correlated
-1.17%
More

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.43%
PFE - BIIB
58%
Loosely correlated
-0.85%
MRK - BIIB
55%
Loosely correlated
-1.17%
AMGN - BIIB
53%
Loosely correlated
+0.49%
NVS - BIIB
48%
Loosely correlated
+0.88%
BMY - BIIB
47%
Loosely correlated
+0.60%
More